Vallon Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2018-01-01
- Employees
- 7
- Market Cap
- -
- Website
- http://www.vallon-pharma.com
Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
Phase 1
Completed
- Conditions
- NarcolepsyADHD
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Vallon Pharmaceuticals, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04647903
- Locations
- 🇺🇸
Vallon Investigational Site, Salt Lake City, Utah, United States
Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)
Phase 1
Completed
- Conditions
- NarcolepsyADHD
- Interventions
- Drug: ADAIR 10mg IR capsules
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Vallon Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04232644
- Locations
- 🇨🇦
BioPharma Services Inc., Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath